secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0001558370-22-008849
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hookipa Q1 net loss $18.0M; cash rises to $141.8M on Gilead deal
----------------------------------------------------------------

- Cash, equivalents and restricted cash $141.8M (Dec 2021: $66.9M) from Gilead collaboration and follow-on financing.
- Revenue $1.4M vs $5.3M Q1 2021; $19M in milestone/initiation fees deferred for future recognition.
- R&D expenses $16.6M (down from $20.2M); net loss $18.0M vs $17.2M in prior-year quarter.
- Gilead HIV program advanced: $4M milestone, $15M initiation fee, $35M equity commitment; up to $237M milestones plus royalties.
- HB-200 Phase 1 data due mid-2022; Phase 2 combo with pembrolizumab data in 2H 2022; prostate cancer IND expected Q3 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000155837022008849/0001558370-22-008849-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000155837022008849/hook-20220516x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-008849

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer